For Healthcare Professionals

A Study of ZN-c3 in Participants With Solid Tumors


About the study

This is a Phase 1 open-label, multicenter study of ZN-c3 monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


  • Major Eligibility Criteria:
    1. Age ≥ 18 years or the minimum legal adult age (whichever is greater) at the time of informed consent.
    2. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
    3. Adequate hematologic and organ function.
    4. Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception and for 6 months and 90 days, respectively, after the last dose of ZN-c3.

    Dose Escalation Inclusion Criteria:

    1. Subjects must have a solid tumor with advanced or metastatic disease, refractory to standard therapy or for whom no standard therapy is available, or the subject is ineligible for standard therapy(ies).
    2. Measurable or evaluable disease per RECIST version 1.1.

    Food Effect Cohort Inclusion Criteria:

    1. Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
    2. Subjects must have no relevant dietary restrictions, and be willing to consume a high-calorie, high-fat breakfast and other standard meals provided during the study.

    Dose Expansion Inclusion Criteria:

    1. Measurable disease, defined as at least one lesion that can be accurately measured per RECIST version 1.1 criteria.
    2. Recurrent or persistent USC or locally advanced or metastatic malignancy with one or more relevant biomarkers related to deoxyribonucleic acid (DNA) damage pathways.


    Major Exclusion Criteria:

    1. Prior therapy with ZN-c3 or known hypersensitivity to any drugs similar to ZN-c3 in class or any inactive ingredients present in ZN-c3.
    2. Prior therapy with a WEE1 inhibitor.
    3. A serious illness or medical condition(s).
    4. Unresolved toxicity of Grade >1 attributed to any prior therapies (excluding Grade ≤2 neuropathy, alopecia or skin pigmentation).
    5. Pregnant or lactating females (including the cessation of lactation) or females of childbearing potential who have a positive serum pregnancy test within 14 days prior to C1D1.
    6. Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.
    7. 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of >480 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.
    8. History or current evidence of congenital or family history of long QT syndrome or Torsade de Pointes (TdP).
    pin location

    Study Locations

    Enter your ZIP code/Postal code/PIN code to locate study sites near you:

    How to Apply

    Contact the study center to learn if this study is a good match for you.

    Study’s details


    Solid Tumor

    Age (in years)



    Phase 1

    Participants needed


    Est. Completion Date

    Aug 31, 2023

    Treatment type



    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc identifier


    Study number


    Understanding Clinical Trials

    Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


    Sign up to save your favorites, 
    receive newsletters, resources, and alerts 
    about clinical trials related to your conditions of interest.